SCHEMBL6073789

SCHEMBL6073789

CN1CCN(C(=O)Nc2ccc3cnc(Nc4ccc(N5CCN(C(=O)OC(C)(C)C)CC5)cc4)nc3n2)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCND3 P30281 4/20 0.53
CCNA2 P20248 2/20 0.53
CDK2 P24941 2/20 0.53
CCNK O75909 1/20 0.53
CDK9 P50750 1/20 0.53
CDK6 Q00534 1/20 0.53
NAMPT P43490 1/20 0.51
EGFR P00533 1/20 0.51
CDK4 P11802 3/20 0.49
CCND1 P24385 3/20 0.49
CCND2 P30279 3/20 0.49
SYK P43405 2/20 0.49
JAK2 O60674 4/20 0.49
FLT3 P36888 1/20 0.49
MAPT P10636 2/20 0.49
MEN1 O00255 1/20 0.49
TSHR P16473 1/20 0.49
KMT2A Q03164 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
JAK3 P52333 5/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6073647 0.97 CDK2 (0.56) CCND3CCNA2CDK2CCNKCDK9
SCHEMBL6073565 0.93 CCND3 (0.53) CCND3CCNA2CDK2CCNKCDK9
SCHEMBL6074138 0.88 CDK2 (0.58) CCND3CCNA2CDK2CCNKCDK9
SCHEMBL6073911 0.87 CDK2 (0.54) CCND3CCNA2CDK2CCNKCDK9
SCHEMBL6073333 0.86 CCND3 (0.51) CCND3CCNA2CDK2CCNKCDK9
SCHEMBL6074236 0.86 CDK2 (0.53) CCND3CCNA2CDK2CCNKCDK9
SCHEMBL6074107 0.85 CDK2 (0.51) CCND3CCNA2CDK2CCNKCDK9
SCHEMBL6073855 0.84 CDK4 (0.54) CCND3CCNA2CDK2CCNKCDK9
SCHEMBL6074010 0.83 CDK2 (0.59) CCND3CCNA2CDK2CCNKCDK9
SCHEMBL6073880 0.83 CDK4 (0.54) CCND3CCNA2CDK2CCNKCDK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7053070-B2 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors WARNER-LAMBERT COMPANY (US) 2006-05-30 US disclosed
US-20030073668-A1 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors BOOTH RICHARD JOHN (US) 2003-04-17 US disclosed
EP-1254137-A1 PYRIDO 2,3-d]PYRIMIDINE-2,7-DIAMINE KINASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2002-11-06 EP disclosed
WO-2001055147-A1 PYRIDO[2,3-d]PYRIMIDINE-2,7-DIAMINE KINASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2001-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073668-A1 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors CDK9, CDK19, CDK3 CCND3 98/4885CCNA2 67/4885CDK2 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.